$VINC
Vincerx Pharma, Inc.

2022 Q4 Form 10-Q Financial Statement

#000119312522282658 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.050M $4.525M $5.720M
YoY Change -24.57% -20.89%
% of Gross Profit
Research & Development $11.37M $11.07M $12.21M
YoY Change -7.82% -9.38%
% of Gross Profit
Depreciation & Amortization $14.00K $13.00K
YoY Change -44.0%
% of Gross Profit
Operating Expenses $15.42M $16.90M $17.93M
YoY Change -12.9% -5.74% 3971.66%
Operating Profit -$16.90M -$17.93M
YoY Change -5.74% 3971.66%
Interest Expense $429.0K $125.0K -$6.606M
YoY Change -96.19% -101.89% -66160.0%
% of Operating Profit
Other Income/Expense, Net $1.351M $22.00K $13.00K
YoY Change -6533.33% 69.23%
Pretax Income -$13.64M -$16.88M -$24.52M
YoY Change 110.8% -31.17% 5603.26%
Income Tax
% Of Pretax Income
Net Earnings -$13.64M -$16.88M -$24.52M
YoY Change 110.8% -31.17% 5546.74%
Net Earnings / Revenue
Basic Earnings Per Share -$0.80 -$1.39
Diluted Earnings Per Share -$0.65 -$0.80 -$1.386M
COMMON SHARES
Basic Shares Outstanding 21.19M 21.19M 17.69K
Diluted Shares Outstanding 21.08K 17.69K

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $52.46M $65.97M $122.8M
YoY Change -52.93% -46.27% 21827.86%
Cash & Equivalents $11.66M $45.80M $122.8M
Short-Term Investments $40.80M $20.17M
Other Short-Term Assets $3.301M $746.0K $452.0K
YoY Change 3374.74% 65.04% 545.71%
Inventory
Prepaid Expenses $134.0K $470.0K
Receivables
Other Receivables
Total Short-Term Assets $55.96M $67.26M $123.2M
YoY Change -49.96% -45.43% 19157.5%
LONG-TERM ASSETS
Property, Plant & Equipment $177.0K $188.0K $4.419M
YoY Change -24.03% -95.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $81.00K $1.642M $1.758M
YoY Change -95.1% -6.6%
Total Long-Term Assets $3.322M $5.121M $6.177M
YoY Change -43.07% -17.1% -90.6%
TOTAL ASSETS
Total Short-Term Assets $55.96M $67.26M $123.2M
Total Long-Term Assets $3.322M $5.121M $6.177M
Total Assets $59.29M $72.38M $129.4M
YoY Change -49.62% -44.08% 95.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.065M $4.393M $2.259M
YoY Change 51.81% 94.47% 464.75%
Accrued Expenses $4.923M $4.445M $532.0K
YoY Change 4.41% 735.53%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.156M $9.950M $25.16M
YoY Change -34.22% -60.46% 6190.5%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $50.00K $50.00K $3.637M
YoY Change -98.54% -98.63% 58.13%
Total Long-Term Liabilities $50.00K $50.00K $3.637M
YoY Change -98.54% -98.63% 10.21%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.156M $9.950M $25.16M
Total Long-Term Liabilities $50.00K $50.00K $3.637M
Total Liabilities $11.62M $12.67M $28.80M
YoY Change -33.06% -56.01% 678.43%
SHAREHOLDERS EQUITY
Retained Earnings -$121.3M -$107.7M
YoY Change 116.79%
Common Stock $2.000K $2.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $47.67M $59.71M $100.6M
YoY Change
Total Liabilities & Shareholders Equity $59.29M $72.38M $129.4M
YoY Change -49.62% -44.08% 95.11%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$13.64M -$16.88M -$24.52M
YoY Change 110.8% -31.17% 5546.74%
Depreciation, Depletion And Amortization $14.00K $13.00K
YoY Change -44.0%
Cash From Operating Activities -$13.82M -$14.87M -$10.30M
YoY Change 20.29% 44.33% 8351.1%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$22.00K
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$20.38M -$20.20M $0.00
YoY Change
Cash From Investing Activities -$20.38M -$20.20M -$22.00K
YoY Change 254687.5% 91695.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $47.50M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 38.00K 0.000 47.50M
YoY Change -86.57% -100.0%
NET CHANGE
Cash From Operating Activities -13.82M -14.87M -10.30M
Cash From Investing Activities -20.38M -20.20M -22.00K
Cash From Financing Activities 38.00K 0.000 47.50M
Net Change In Cash -34.16M -35.07M 37.17M
YoY Change 204.72% -194.33% -30588.42%
FREE CASH FLOW
Cash From Operating Activities -$13.82M -$14.87M -$10.30M
Capital Expenditures $0.00 $0.00 -$22.00K
Free Cash Flow -$13.82M -$14.87M -$10.28M
YoY Change 20.38% 44.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001796129
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39244
dei Entity Registrant Name
EntityRegistrantName
Vincerx Pharma, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-3197402
dei Entity Address Address Line1
EntityAddressAddressLine1
260 Sheridan Avenue, Suite 400
dei Entity Address City Or Town
EntityAddressCityOrTown
Palo Alto
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94306
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
800-6676
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
VINC
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21189769
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45804000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
111459000
CY2022Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
64000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
105000
CY2022Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
20171000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
0
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
470000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
182000
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
746000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
95000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
67255000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
111841000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3291000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3949000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
188000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
233000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1642000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1653000
CY2022Q3 us-gaap Assets
Assets
72376000
CY2021Q4 us-gaap Assets
Assets
117676000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4393000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2019000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4445000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4715000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
999000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
738000
CY2022Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
113000
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
6447000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
9950000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13919000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2669000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3436000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
50000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2022Q3 us-gaap Liabilities
Liabilities
12669000
CY2021Q4 us-gaap Liabilities
Liabilities
17355000
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21189769
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21189769
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21057560
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21057560
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
2000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
167463000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
156311000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-63000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-21000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-107695000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-55971000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
59707000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
100321000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
72376000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
117676000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4525000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5720000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14903000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17206000
CY2022Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
11066000
CY2021Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
12211000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
40779000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
27743000
CY2022Q3 us-gaap Restructuring Charges
RestructuringCharges
1310000
CY2021Q3 us-gaap Restructuring Charges
RestructuringCharges
0
us-gaap Restructuring Charges
RestructuringCharges
2469000
us-gaap Restructuring Charges
RestructuringCharges
0
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
16901000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
17931000
us-gaap Operating Expenses
OperatingExpenses
58151000
us-gaap Operating Expenses
OperatingExpenses
44949000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-16901000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-17931000
us-gaap Operating Income Loss
OperatingIncomeLoss
-58151000
us-gaap Operating Income Loss
OperatingIncomeLoss
-44949000
CY2022Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
79000
CY2021Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
6606000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6334000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-12102000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
204000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
0
us-gaap Investment Income Interest
InvestmentIncomeInterest
204000
us-gaap Investment Income Interest
InvestmentIncomeInterest
0
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-103000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
13000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-111000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
13000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
22000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6593000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6427000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
12115000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-16879000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-24524000
us-gaap Net Income Loss
NetIncomeLoss
-51724000
us-gaap Net Income Loss
NetIncomeLoss
-32834000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
14000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-19000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
39000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-19000
CY2022Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-81000
CY2021Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
0
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-81000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
0
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16946000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24543000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-51766000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32853000
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.8
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.8
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.39
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.46
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.06
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21083
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21083
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17694
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17694
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20992
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20992
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15941
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15941
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
74363000
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
2290000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
14000
CY2022Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-81000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-16879000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
59707000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
100321000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
242000
us-gaap Share Based Compensation
ShareBasedCompensation
10910000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
39000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-81000
us-gaap Net Income Loss
NetIncomeLoss
-51724000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
59707000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
71595000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
3251000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
47499000
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
6075000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-19000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-24524000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
100626000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
25379000
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
3251000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
47499000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
40671000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2503000
us-gaap Share Based Compensation
ShareBasedCompensation
17427000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-19000
us-gaap Net Income Loss
NetIncomeLoss
-32834000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
100626000
us-gaap Profit Loss
ProfitLoss
-51724000
us-gaap Profit Loss
ProfitLoss
-32834000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
40000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
0
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
10910000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
17427000
vinc Amortization Of Right Of Use Assets Liabilities
AmortizationOfRightOfUseAssetsLiabilities
658000
vinc Amortization Of Right Of Use Assets Liabilities
AmortizationOfRightOfUseAssetsLiabilities
-3000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6334000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-12102000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
57000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
939000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-866000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-11000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1676000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2374000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1749000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-270000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4668000
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
0
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-14000
vinc Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-506000
vinc Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
3000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
50000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45787000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21916000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
20195000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
0
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
5000000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
0
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
250000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-20195000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5250000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
242000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
47499000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
40671000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
242000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
88170000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
44000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-65696000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
61004000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
111564000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61792000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45868000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
122796000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
25000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
2503000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4169000
us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 1. NATURE OF BUSINESS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LSAC was initially formed on December 19, 2018 as a Delaware corporation for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. In December 2020, the Merger Sub merged with and into Legacy Vincera Pharma, with Legacy Vincera Pharma surviving the Merger as a wholly- owned subsidiary of LSAC. In connection with the Business Combination, LSAC changed its name to Vincera Pharma, Inc., and subsequently in January 2021, changed its name to Vincerx Pharma, Inc. (together with its consolidated subsidiaries, the “Company”). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company is a clinical-stage biopharmaceutical company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The Company’s current pipeline is entirely derived from the Bayer License Agreement (see Note 3), pursuant to which the Company has been granted an exclusive, royalty-bearing, worldwide license under certain Bayer patents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> to develop, use, manufacture, commercialize, sublicense and distribute a clinical-stage and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-on</div> small molecule drug program and a preclinical stage bioconjugation platform, which includes next-generation antibody-drug conjugates and small molecule drug conjugates. The Company intends to use these product candidates to treat various cancers in a patient-specific, targeted approach. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our business operations, and those of third parties with whom we conduct business, have been, and could continue to be, adversely affected by health pandemics and epidemics, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> and by economic, business and political events, including inflation and the war in Ukraine. The extent to which these factors could continue to impact our business and operations will depend on future developments that are highly uncertain and cannot be predicted with confidence. Management continues to evaluate the impact of these factors on our current operations and future plans and intends to take appropriate measures to help alleviate their impact, but there can be no assurance that these efforts will be successful and that these factors will not continue to have a negative effect on the Company’s financial position and results of its operations. </div>
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-12-19
vinc Date Of Licence Agreement
DateOfLicenceAgreement
2020-10-07
CY2021Q1 vinc Licence Fee Paid
LicenceFeePaid
5000000
CY2022Q3 vinc Aggregate Milestone Payments Payable
AggregateMilestonePaymentsPayable
1000000000
us-gaap Use Of Estimates
UseOfEstimates
<div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of commitments and contingencies at the date of the financial statements as well as reported amounts of expenses during the reporting periods. Estimates made by the Company include, but are not limited to, those related to our accrued clinical trial and manufacturing expenses, common stock warrant liabilities and stock-based compensation. The Company bases these estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates. </div></div>
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2022Q2 vinc Percentage Of Employees Reduction
PercentageOfEmployeesReduction
0.33
CY2022Q3 us-gaap Restructuring And Related Cost Expected Cost1
RestructuringAndRelatedCostExpectedCost1
2500000
CY2022Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
50123000
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
50204000
us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
0
us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
81000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
50123000
CY2020Q4 vinc Date Of Lease Agreement
DateOfLeaseAgreement
P5Y
CY2020Q4 vinc Date Of Lease Commencement
DateOfLeaseCommencement
2021-01-01
CY2020Q4 us-gaap Lease Cost
LeaseCost
1100000
CY2022Q3 vinc Lessee Operating Sub Lease Rent Amount
LesseeOperatingSubLeaseRentAmount
50000000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
3700000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3300000
CY2022Q3 vinc Lessee Operating Sub Lease Term Of Contract
LesseeOperatingSubLeaseTermOfContract
P18M
CY2022Q3 us-gaap Sublease Income
SubleaseIncome
150000000
us-gaap Sublease Income
SubleaseIncome
150000000
us-gaap Operating Lease Cost
OperatingLeaseCost
897000
us-gaap Operating Lease Cost
OperatingLeaseCost
216000
us-gaap Variable Lease Cost
VariableLeaseCost
0
us-gaap Variable Lease Cost
VariableLeaseCost
0
us-gaap Lease Cost
LeaseCost
897000
us-gaap Lease Cost
LeaseCost
216000
us-gaap Operating Lease Payments
OperatingLeasePayments
743000
us-gaap Operating Lease Payments
OperatingLeasePayments
216000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4169000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y3M18D
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y3M18D
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.08
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.08
CY2022Q3 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
304000
CY2022Q3 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
1261000
CY2022Q3 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
1284000
CY2022Q3 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
1336000
CY2022Q3 us-gaap Contractual Obligation
ContractualObligation
4185000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
517000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
3668000
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21057560
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21189769
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
3408
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.74
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y2M12D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1881
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.13
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
965
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
15.44
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4324
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.12
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M18D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
2141
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
18.08
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y3M18D
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
7.2
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P0Y10M24D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
4.13
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
18.8
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.836
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.775
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.025
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.009
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2290000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6075000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10910000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17427000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-16879000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-24524000
us-gaap Net Income Loss
NetIncomeLoss
-51724000
us-gaap Net Income Loss
NetIncomeLoss
-32834000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21083
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21083
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17694
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17694
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20992
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20992
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15941
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15941
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.8
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.8
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.39
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.39
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.46
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.06
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7619000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6666000

Files In Submission

Name View Source Status
0001193125-22-282658-index-headers.html Edgar Link pending
0001193125-22-282658-index.html Edgar Link pending
0001193125-22-282658.txt Edgar Link pending
0001193125-22-282658-xbrl.zip Edgar Link pending
d237140d10q.htm Edgar Link pending
d237140dex101.htm Edgar Link pending
d237140dex311.htm Edgar Link pending
d237140dex312.htm Edgar Link pending
d237140dex321.htm Edgar Link pending
d237140dex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
d237140d10q_htm.xml Edgar Link completed
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vinc-20220930.xsd Edgar Link pending
vinc-20220930_def.xml Edgar Link unprocessable
vinc-20220930_lab.xml Edgar Link unprocessable
vinc-20220930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
vinc-20220930_cal.xml Edgar Link unprocessable